Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Premature Ejaculation - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Premature Ejaculation - Pipeline Review, H2 2016, provides an overview of the Premature Ejaculation (Male Health) pipeline landscape. Premature ejaculation (PE) is also known as rapid ejaculation, is the most common type of sexual dysfunction in men. Ejaculation is controlled by the central nervous system. This happens when sexual stimulation and friction provide impulses that are delivered to the spinal cord and into the brain. The predisposing factors include erectile dysfunction, stress and certain medications that influence the action of chemical messengers in the brain (psychotropics) may contribute to premature ejaculation. Treatment includes topical anesthetic creams and antidepressants. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Premature Ejaculation - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Premature Ejaculation (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Premature Ejaculation (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Ejaculation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively for Premature Ejaculation. Premature Ejaculation (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Premature Ejaculation (Male Health). - The pipeline guide reviews pipeline therapeutics for Premature Ejaculation (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Premature Ejaculation (Male Health) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Premature Ejaculation (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Premature Ejaculation (Male Health) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Premature Ejaculation (Male Health). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Premature Ejaculation (Male Health) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Premature Ejaculation Overview 6 Therapeutics Development 7 Pipeline Products for Premature Ejaculation - Overview 7 Premature Ejaculation - Therapeutics under Development by Companies 8 Premature Ejaculation - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Premature Ejaculation - Products under Development by Companies 12 Premature Ejaculation - Companies Involved in Therapeutics Development 13 Allergan Plc 13 Ixchelsis Limited 14 NeuroHealing Pharmaceuticals Inc. 15 Plethora Solutions Holdings Plc 16 SK Chemicals Co., Ltd. 17 Premature Ejaculation - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Combination Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 (lidocaine + prilocaine) - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 IX-01 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 modafinil - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 NCE-405 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 onabotulinumtoxin A - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Premature Ejaculation - Dormant Projects 40 Premature Ejaculation - Discontinued Products 41 Premature Ejaculation - Product Development Milestones 42 Featured News & Press Releases 42 Jan 25, 2016: Ixchelsis Announces Positive Clinical Proof of Concept Results for IX-01 in Treating Premature Ejaculation 42 Nov 11, 2014: Plethora Solutions Provides Company Update 42 Oct 07, 2014: PSD502 To Be Marketed As Fortacin Throughout The EU 43 Mar 26, 2014: Plethora Solutions Announces Manufacturing Appointment 44 Mar 11, 2014: Plethora Solutions Provides Company update 44 Nov 19, 2013: Plethora Solutions Receives European Commission Approval For PSD502 To Treat Premature Ejaculation 45 Sep 19, 2013: Plethora Solutions Receives CHMP Positive Opinion For Lidocaine/Prilocaine Plethora For Treatment Of Primary Premature Ejaculation 45 Jul 01, 2013: AGM Statement & PSD502 Regulatory Update 46 Jun 11, 2012: Plethora Provides PSD502 Regulatory Submission Update 46 Mar 15, 2012: Plethora Provides Update On Regulatory Submission Of PSD502 47 Dec 19, 2011: Plethora Provides Update On PSD502 48 Jun 01, 2010: Shionogi Pharma Presents Data On PSD502 For Primary Premature Ejaculation 48 May 26, 2010: Shionogi Pharma Announces Five Clinical Presentations On PSD502 For Primary Premature Ejaculation At AUA Annual Meeting 49 Nov 19, 2009: Sciele Pharma Presents Pivotal Study For PSD502, The First Potential Treatment For Premature Ejaculation At The Sexual Medicine Society Of North America (SMSNA) 49 Aug 21, 2009: NeuroHealing Announces Formation Of Medical Advisory Board For NH02D Program 50 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53
List of Tables
Number of Products under Development for Premature Ejaculation, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Comparative Analysis by Early Stage Development, H2 2016 11 Products under Development by Companies, H2 2016 12 Premature Ejaculation - Pipeline by Allergan Plc, H2 2016 13 Premature Ejaculation - Pipeline by Ixchelsis Limited, H2 2016 14 Premature Ejaculation - Pipeline by NeuroHealing Pharmaceuticals Inc., H2 2016 15 Premature Ejaculation - Pipeline by Plethora Solutions Holdings Plc, H2 2016 16 Premature Ejaculation - Pipeline by SK Chemicals Co., Ltd., H2 2016 17 Assessment by Monotherapy Products, H2 2016 18 Assessment by Combination Products, H2 2016 19 Number of Products by Stage and Target, H2 2016 21 Number of Products by Stage and Mechanism of Action, H2 2016 23 Number of Products by Stage and Route of Administration, H2 2016 25 Number of Products by Stage and Molecule Type, H2 2016 27 Premature Ejaculation - Dormant Projects, H2 2016 40 Premature Ejaculation - Discontinued Products, H2 2016 41
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.